Tag Archives: startups

Kobe Biomedical Innovation Cluster (KBIC) Joins RESI JPM 2026 as Gold Sponsor

28 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is proud to announce that the Kobe Biomedical Innovation Cluster (KBIC) will serve as a sponsor for RESI JPM 2026, continuing its mission to promote innovation, entrepreneurship, and global collaboration in life sciences. 

As part of this sponsorship, KBIC will host the Kansai Life Sciences Accelerator Program (KLSAP) 2025 Demo Day at RESI JPM 2026 on Tuesday, January 13, 12:00 – 2:00pm PT at the Marriott Marquis San Francisco. The Demo Day will feature 3 startups that are part of the KLSAP 2025 Cohort as well as other member companies of KBIC, to be announced as the event approaches. This initiative will provide participating companies with global exposure, strategic investor connections, and the opportunity to pitch to an international audience of early-stage investors and strategic partners across life science and healthcare sectors.

Interested in joining and receiving updates on the KLSAP 2025 Demo Day? Please contact Claire Jeong, VP of Investor Research, Asia BD, at c.jeong@lifesciencenation.com.  

Introduction of Kobe Biomedical Innovation Cluster (KBIC)
Located in the heart of Kobe, Japan, the Kobe Biomedical Innovation Cluster is one of the nation’s leading ecosystems dedicated to the advancement of biomedical research and commercialization. With more than 340 organizations, including research institutes, hospitals, and life science companies, KBIC plays a vital role in bridging academia, government, and industry to accelerate innovation and improve global health outcomes. 

By partnering with RESI JPM 2026, KBIC aims to strengthen international collaboration and support Japanese startups seeking to expand their networks and raise global awareness for their technologies. Through this continued engagement, KBIC and LSN will work together help founders access global capital and strategic resources to advance from concept to commercialization. 

About Kansai Life Sciences Accelerator Program (KLSAP)
Powered by KBIC, the Kansai Life Sciences Accelerator Program (KLSAP) supports early-stage life science and healthcare startups in the Kansai region through tailored mentorship, commercialization guidance, and access to global investor networks. 

The 2025 KLSAP Cohort will participate in RESI JPM 2026 to present their innovations to a diverse investor audience, gain valuable feedback, and establish partnerships that can help drive their technologies toward global markets. The cohort’s participation exemplifies KBIC’s commitment to supporting international expansion and facilitating cross-border collaboration in life sciences. 3 companies have been selected for this year’s KLSAP Cohort, with descriptions of each company added below:

C-Biomex
Founded in 2017, C-Biomex is a bio-venture dedicated to advancing novel theranostics using its proprietary peptide discovery platform, CUS™. The platform enables identification of peptides with high stability and specificity through a three-step process involving a high-purity library, an innovative screening protocol that minimizes background interactions, and direct sequencing via a proprietary algorithm. C-Biomex focuses on radiopharmaceutical development, positioning itself at the intersection of diagnostics and therapeutics to accelerate peptide-based solutions for global biomedical applications.

GeneMedicine
GeneMedicine, founded in 2014 and based in Seoul, develops oncolytic viruses engineered to selectively replicate in and kill cancer cells while stimulating an anti-tumor immune response. Its GM-oAd platform is designed for systemic delivery of oncolytic adenoviruses with enhanced tumor specificity, immune activation, and ability to overcome physical tumor barriers. In addition to its therapeutic pipeline, GeneMedicine is expanding into CDMO services and novel drug-delivery systems, building a sustainable and diversified business model.

iXgene
iXgene is a Japanese life sciences company focused on developing therapies for intractable diseases using genome editing and induced pluripotent stem (iPS) cell technology. Its proprietary platform combines advanced genome editing tools, such as CRISPR, with iPS-derived therapeutics targeting indications including malignant brain tumors and brain injury. iXgene collaborates with academic institutions and pharmaceutical partners to translate next-generation regenerative and gene therapies into the clinic, aiming to address high-unmet-need central nervous system diseases. 

LSN and KBIC invites all investors, industry leaders, and innovators to meet the KLSAP 2025 Cohort at RESI JPM 2026. Together, they will continue to advance global innovation and foster meaningful connections across the life sciences ecosystem. 

Register for RESI JPM

Tags: , , , , , , , , , ,

RESI London 2025: Dec 4! See feedback from previous attendees about the UK’s biggest investment conference!

21 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

RESI London 2025 will be the second year of the UK’s biggest life science investor conference. We expect 250 investors, ready to finance your company. The RESI partnering system allows you to schedule face to face meetings with each investor. See what last year’s attendees are saying!

Testimonials

“RESI London was an extremely productive experience for my company, and the partnering system was so easy to use.”

– Nick Sireau, CEO, Serenatis Bio

“RESI is the go-to meeting for biotech CEOs’ seeking early stage capital. They have built an early stage platform educating founders and bringing capital to them. They are the only people serving this under loved sub sector with such passion.”

– Sunil Shah, CEO, O2h Ventures & Co-founder, O2h Group

“Attending RESI London for the first time was a refreshing and highly positive experience. The event exceeded my expectations in several ways. The atmosphere was welcoming and collaborative, which created a conducive environment for meaningful interactions. What stood out most was the exposure to a unique group of investors—those with a specific interest in early-stage, cutting-edge technologies. These are exactly the type of investors we aim to connect with at Rinri, so the conference provided an excellent platform to engage with individuals who understand the risks and rewards of innovative science-driven ventures.”

– Simon Chandler, CEO, Rinri Therapeutics

“My session was punctual and well-organized. The jury members were thoughtfully selected and provided insightful, constructive feedback that was highly valuable.”

– Christine Ruckenbauer, CBO, RIANA Therapeutics

“I highly value RESI and am grateful for the opportunity both to contribute as a pitch judge, company scouting and the networking opportunities. You have a dynamic network with easy, friendly, professional access. Thanks for all you are doing for the life science and tech development sector.”

– Jill Sorensen, MTEC (Investor)

“As One Nucleus seeks to enable our members to engage with the widest possible investor pool, partnering with RESI London creates a unique opportunity to bring our members into contact with new global early-stage investors to complement the known local investors they meet at all other early-stage pitching events in the UK.”

– Tony Jones, CEO, One Nucleus

“We started this as a grassroots meeting with One Nucleus, and it has been extremely gratifying and rewarding to see our international investors attending because the UK, we know, has some great science that needs to get to the global stage. We are expecting 250+ investors.”

– Dennis Ford, CEO, Life Science Nation

Register RESI London by Friday, October 24 to save £200 on early bird rates!

Register for RESI London Appy to Pitch at RESI London

Tags: , , , , , , , , , , , , , , , , , , ,

Confirmed Investors at RESI London 2025 

21 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is thrilled to announce the confirmed investors for RESI London 2025, taking place on December 4, at King’s Fund, 11 Cavendish Square, with virtual partnering on December 8–9. This premier event connects early-stage life science companies with a diverse array of global investors, facilitating meaningful partnerships and funding opportunities.

Meet the Confirmed Investors

RESI London 2025 will feature a robust lineup of investors spanning various sectors within the life sciences industry. Confirmed investors include:

This diverse group of investors represents a broad spectrum of interests, from pharmaceutical giants to specialized venture capital firms, ensuring that attendees have access to a wealth of expertise and potential funding sources.

Why Attend RESI London 2025?

RESI London 2025 provides an exceptional platform for early-stage companies to engage directly with top-tier investors across the life sciences industry, present innovations to a panel of esteemed judges in the Innovator’s Pitch Challenge (IPC), and receive valuable feedback. Attendees will have the opportunity to expand their network by building relationships with potential partners, collaborators, and industry experts, while also continuing discussions and meetings through virtual partnering on December 8–9, extending their reach and maximizing opportunities.

Whether you’re seeking funding, partnerships, or strategic alliances, RESI London 2025 provides the resources and connections necessary to propel your venture forward.

Register for RESI London >>

Tags: , , , , , , , , , ,

Make the Most of JPM Week with Sunday Partnering at the Marriott Marquis 

21 Oct

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

JPM week is coming fast, and the best opportunities go to those who plan early. If you still haven’t secured a venue or partnering space, Life Science Nation (LSN) has your solution. As the host of RESI JPM, LSN is opening Sunday partnering at the Marriott Marquis, giving attendees an extra day to meet face-to-face with fellow RESI participants or connect informally outside the partnering system before the main event begins.

Sunday partnering provides a head start on the biggest week in healthcare investment, whether you’re scheduling investor meetings, gathering your team, or hosting your own private event. The Marriott Marquis is at the center of the JPM ecosystem, making it the perfect base for receptions, showcases, and partnering tables throughout the week.

If you represent a membership organization, this is your chance to give your members valuable exposure and a convenient home base in San Francisco—without the steep prices other hotels are charging for table rentals. And for product or service providers, sponsoring or exhibiting at RESI remains the most direct and cost-effective way to meet early-stage innovators. Unlike other partnering events, RESI’s community welcomes vendor meetings, and our partnering stats show that clearly.

Life Science Nation is here to help you make the most of the biggest week of the year. Whether you’re planning a private reception, setting up a partnering table, or joining RESI as an exhibitor, our team can help you build visibility, secure meetings, and connect with the early-stage life science community that gathers at JPM each January.

Register RESI JPM by Friday, October 24 to save $600 on early bird rates!

Register for RESI JPM >>

Tags: , , , , , , , , , , , , , , , , ,

LSN Ecosystem Deal Matrix $1.29 Billion and Counting 

15 Oct

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022Across Life Science Nation (LSN)’s interconnected network, from the Investor & Licensing Partner Database and RESI Conference Series to LSN Labs, 90 companies have publicly disclosed raising capital or signing licensing deals sourced directly through LSN.  LSN has been collecting this disclosed data and, after reaching 90 deals, wanted to extrapolate the compelling metrics behind the LSN engine that facilitated the deals, known as the LSN Ecosystem.

Together, they’ve secured $1.29 billion in verified funding. When factoring in the broader global community of 9,000+ startups that have engaged with LSN tools and programs and gone through the RESI turnstiles, the estimated impact reaches $6.4 billion. This isn’t modeled data; these are real companies, real partners, and real outcomes. It’s proof that structured global partnering delivers measurable success.

A Marketplace That Works — and Scales

At first glance, the dataset lists 90 companies and 52 investors. On closer inspection, that ratio reflects how healthy marketplaces behave. Each transaction represents multiple funding relationships, roughly 100 to 150 discrete deals in total, many of which are undisclosed but very much real.

  • For startups, closing $1.29 billion through LSN-facilitated partnerships signals one of the strongest verified conversion rates in early-stage life sciences.
  • For investors, repeat participation by six global funds, including corporate venture, pharma, and family offices, demonstrates a growing cycle of trust and sourcing efficiency within LSN’s ecosystem.

This is not a collection of introductions; it’s a living marketplace where structure, data, and discipline transform intro meetings into ongoing dialogue, building relationships that ultimately lead to transactions.

Where the Money Moves: The Four Domains (4Ds)

SECTOR DISCLOSED FUNDING ($) % SHARE COMMENT
Drugs (Therapeutics) 1,106,490,000 83% Core growth engine for global biotech
Devices (Medtech) 120,820,000 9% Strategic investments and exits rising
Diagnostics & Tools 111,330,000 8% A precision frontier gaining traction
Digital Health Emerging (<1%) — Expanding rapidly as AI matures and the software moves adroitly

Therapeutics dominate the dollars, but the deal flow is distributed, indicating a balanced and resilient early-stage market that spans drugs, devices, diagnostics, and digital health alike.

Even Distribution, Uneven Costs

It’s no surprise that therapeutics absorb most of the capital; drug development is costly and front-loaded. A single preclinical or IND-enabling round can match the combined raises of multiple device or diagnostics startups. But when you look at deal volume, not just deal size, the picture changes. The 90 funded companies are evenly distributed across the 4Ds:

SECTOR  COMPANIES FUNDED  SHARE OF TOTAL 
Drugs (Therapeutics)  31 34%
Diagnostics & Tools  26 29%
Devices (Medtech)  23 26%
Digital Health  10 11%

The big money may flow into drugs, but the deals are happening across all four domains. That balance defines a healthy market, diversified, dynamic, and alive.

Average Deal Size Across the 4Ds

SECTOR  AVERAGE RAISE PER COMPANY ($)  INSIGHT 
Drugs (Therapeutics)  $35.7 million Reflects the high capital intensity of preclinical and early clinical development
Devices (Medtech)  $5.3 million Medtech investors focus on de-risked prototypes and regulatory progress
Diagnostics & Tools  $4.3 million Enabling and precision technologies attract steady, mid-range funding
Digital Health  >$3 million Early but fast-growing; deal sizes expected to rise with data maturity

These numbers capture a simple truth: Drug rounds dominate in size, but early-stage innovation thrives across every domain. The LSN ecosystem delivers results across all four, not just where the biggest checks are written.

The Signal: Efficiency Is the New Advantage

As global capital tightens, efficiency wins. With RESI London (Dec 2025) and RESI JPM (Jan 2026) approaching, startups and investors alike are leaning into systems that don’t just connect, they convert. LSN’s rhythm of data, readiness, and disciplined outreach has become the commercialization backbone for early-stage life sciences worldwide.  “At RESI, we don’t chase headlines; we measure outcomes. The companies and investors in this dataset are the proof.”

Join the Momentum. Be Part of the Data.

The next cycle begins now. Don’t miss your chance to access the world’s most effective life science partnering platform.

Registration now open:

  • RESI London 2025 (Dec. 4, 8&9) – [Register]
  • RESI JPM 2026 (Jan.12-14, 19&20)– [Register]
  • RESI Europe 2026 (March 23-25) – [Register]

Tags: , , , , , , , , , , ,

Will PubMed be Shutdown? 

15 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

Many in the life sciences research community were spooked when PubMed went down temporarily in March after the Trump administration cut $4 billion in “indirect costs” that supported medical research. More recently, an ominous message appeared on PubMed: “Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed…” Many who use PubMed but not other government websites were probably panicked by this, but a quick look at clinicaltrials.gov, NIH Reporter and even NIH’s main site reveals the same message, while different versions of this message appear on the websites of HHS, CMS, etc.

Still, various EU governments have been quietly preparing for a PubMed shutdown by ensuring they will have a PubMed-alternative just in case. Of course, let’s be real: while they may be able to serve the existing content in PubMed, they will not be able to suddenly support the thousands of additional abstracts and articles added each day, along with MeSH tagging, journal selection, XML/JSON feeds, and other critical functions PubMed provides.

While PubMed is critical to nearly every life science researcher, even those with access to Web of Science, Embase, etc., it is especially critical to early-stage life science companies and investors. For basic research, competitive intelligence, due diligence and more, PubMed is indispensable for those without access to paid literature databases. PubMed is also an important source for pipeline database providers that investors and pharma use to find assets and perform CI.

The US government, for decades, has supplied a critical and reliable literature resource for worldwide audiences, both professional and non-professional alike. With the addition of the first and best clinical trial registry in 2000, continued funding for this resource is paramount for global biomedical research.

Tags: , , , , , , , , , , , , , , , , , , ,

Host Your JPM Reception, Presentation, Showcase or Partnering at the Marriott Marquis 

15 Oct

By Matt Stanton, VP Sales US West, Central and South America, LSN

JPM is creeping up on you once again, and you still don’t have an event planned. All the good venues are gone and all you’re left with are subprime ones or those with sky-high prices. Why not work with us to plan your best event or partnering table rental at the centrally located Marriott Marquis? RESI JPM will be a two-day event this year: Monday and Tuesday. Life Science Nation has rental space available on Sunday, that will allow you to put your event during what is already a lively ecosystem of early-stage companies and investors. If you already have an event planned, why not do more? If there were ever a time to do more, it’s during JPM.

If you’re a membership organization, you owe it to your members to provide them partnering space at JPM. But getting a partnering table at one of the San Fran hotels will costs at least $1500 per day per table! Contact us to find out how you can get conveniently located partner tables for your members at affordable prices.

Finally, if you’re a product or service provider, sponsoring, exhibiting or attending RESI is, by far, the best opportunity to bang out 50+ meetings with early-stage innovators. RESI is the only partnering conference where companies are more than happy to accept partnering meetings with vendors, as can be seen in our partnering stats. In the RESI partnering system, you won’t find any profiles with the dreaded “no service provider requests”. Additionally, sponsoring or exhibiting at RESI is less than doing so at any of the other main JPM conferences.

See you at JPM!

Secure Your RESI JPM Exhibitor Spot Contact Us to Reserve Event Space

Tags: , , , , , , , ,

← Older Entries
Newer Entries →